Lymphocyte subsets in haematological patients with COVID-19: Multicentre prospective study.

CD4/CD8 ratio COVID-19 Haematological malignancies Lymphocyte subsets NK cells T cells TCR ɣ/ƍ cells

Journal

Translational oncology
ISSN: 1936-5233
Titre abrégé: Transl Oncol
Pays: United States
ID NLM: 101472619

Informations de publication

Date de publication:
Jan 2021
Historique:
received: 08 09 2020
revised: 20 10 2020
accepted: 03 11 2020
entrez: 18 11 2020
pubmed: 19 11 2020
medline: 19 11 2020
Statut: ppublish

Résumé

The role of immune dysregulation in the course and prognosis of COVID-19 is not clearly established. In particular, immune status in specific populations such as haematological patients, who have an impaired immunological system, has not been described so far. Here, we performed a comprehensive analysis of peripheral blood lymphocyte subsets in 27 SARS-CoV-2-infected patients, including 16 patients with haematological malignancies. We identified T cell subpopulations, B cells, NK cells and TCR α/ß and ɣ/ƍ-expressing T cells during COVID-19 infection, with significant changes observed in immune profiles during the course of disease, especially in haematological patients. We observed an increase in activated T lymphocytes (CD3+HLA-DR+ and CD3+CD8+HLA-DR+) in the early stages of SARS-CoV-2 infection with a concomitant decrease in the CD4/CD8 ratio in haematological patients compared to non-haematological patients affected by COVID-19. We also found a decrease in ɣ/ƍ T cells in both studied groups of patients, with lower numbers of CD25+ T cells and CD16+CD56+ NK cells in haematological patients compared to non-haematological patients with COVID-19. Our findings demonstrate, for the first time, impaired adaptive immunity in patients with haematological malignancies infected with COVID-19, resulting in impaired cellular immune responses to SARS-CoV-2. This warrants further investigation of this disease group in COVID-19 patient cohorts.

Identifiants

pubmed: 33204385
doi: 10.1016/j.tranon.2020.100943
pii: S1936-5233(20)30435-6
pmc: PMC7657028
pii:
doi:

Types de publication

Journal Article

Langues

eng

Pagination

100943

Informations de copyright

© 2020 The Authors.

Déclaration de conflit d'intérêts

The authors declare the following financial interests/personal relationships which may be considered as potential competing interests

Références

J Clin Invest. 2020 May 1;130(5):2620-2629
pubmed: 32217835
Lancet. 2020 Apr 11;395(10231):1225-1228
pubmed: 32178769
N Engl J Med. 2020 Apr 30;382(18):1708-1720
pubmed: 32109013
Lancet. 2020 Mar 28;395(10229):1054-1062
pubmed: 32171076
Clin Infect Dis. 2020 Jul 28;71(15):762-768
pubmed: 32161940
J Infect Dis. 2020 Jun 29;222(2):198-202
pubmed: 32379887
Clin Chim Acta. 2020 Sep;508:110-114
pubmed: 32405080
J Infect. 2020 Jul;81(1):e51-e60
pubmed: 32315725
Signal Transduct Target Ther. 2020 Mar 27;5(1):33
pubmed: 32296069
Front Immunol. 2015 Jan 30;5:687
pubmed: 25688241
Klin Wochenschr. 1990 Apr 17;68(8):393-6
pubmed: 1971856
Front Immunol. 2020 May 01;11:827
pubmed: 32425950
J Clin Virol. 2020 Jun;127:104361
pubmed: 32344320
EBioMedicine. 2020 May;55:102763
pubmed: 32361250
Leukemia. 2006 Jan;20(1):29-34
pubmed: 16281063
J Cell Mol Med. 2020 Oct;24(19):11603-11606
pubmed: 32864865
J Infect Dis. 2020 May 11;221(11):1762-1769
pubmed: 32227123
Int J Infect Dis. 2020 Jul;96:131-135
pubmed: 32376308
Clin Exp Immunol. 1993 Sep;93(3):337-43
pubmed: 8103715
Cytometry A. 2020 Aug;97(8):772-776
pubmed: 32542842

Auteurs

Elżbieta Kalicińska (E)

Department and Clinic of Haematology, Blood Neoplasms, and Bone Marrow Transplantation, Wroclaw Medical University, Pasteura Street 4, 50-367 Wroclaw, Poland. Electronic address: elzbieta.kalicinska@umed.wroc.pl.

Donata Szymczak (D)

Department and Clinic of Haematology, Blood Neoplasms, and Bone Marrow Transplantation, Wroclaw Medical University, Pasteura Street 4, 50-367 Wroclaw, Poland.

Iga Andrasiak (I)

WroMedica Research Centre, Wroclaw, Poland.

Aleksandra Bogucka-Fedorczuk (A)

Department and Clinic of Haematology, Blood Neoplasms, and Bone Marrow Transplantation, Wroclaw Medical University, Pasteura Street 4, 50-367 Wroclaw, Poland.

Aleksander Zińczuk (A)

Department of Infectious Diseases and Hepatology, Wroclaw Medical University, Wroclaw, Poland; Department of Forensic Medicine, Wroclaw Medical University, Wroclaw, Poland.

Wojciech Szymański (W)

Department of Infectious Diseases and Hepatology, Wroclaw Medical University, Wroclaw, Poland.

Monika Biernat (M)

Department and Clinic of Haematology, Blood Neoplasms, and Bone Marrow Transplantation, Wroclaw Medical University, Pasteura Street 4, 50-367 Wroclaw, Poland.

Marcin Rymko (M)

Department of Haematology and Bone Marrow Transplantation, SSM im. M. Kopernika, Torun, Poland.

Grażyna Semeńczuk (G)

Department of Haematology, Regional Specialist Hospital, Grudziadz, Poland.

Paula Jabłonowska (P)

Department and Clinic of Haematology, Blood Neoplasms, and Bone Marrow Transplantation, Wroclaw Medical University, Pasteura Street 4, 50-367 Wroclaw, Poland.

Justyna Rybka (J)

Department and Clinic of Haematology, Blood Neoplasms, and Bone Marrow Transplantation, Wroclaw Medical University, Pasteura Street 4, 50-367 Wroclaw, Poland.

Krzysztof Simon (K)

Department of Infectious Diseases and Hepatology, Wroclaw Medical University, Wroclaw, Poland.

Tomasz Wróbel (T)

Department and Clinic of Haematology, Blood Neoplasms, and Bone Marrow Transplantation, Wroclaw Medical University, Pasteura Street 4, 50-367 Wroclaw, Poland.

Classifications MeSH